ILMN

ILMN

USD

Illumina Inc. Common Stock

$77.880-0.120 (-0.154%)

リアルタイム価格

Healthcare
Diagnostics & Research
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$78.000

高値

$79.220

安値

$77.050

出来高

0.17M

企業ファンダメンタルズ

時価総額

12.3B

業種

Diagnostics & Research

United States

取引統計

平均出来高

2.71M

取引所

NMS

通貨

USD

52週レンジ

安値 $68.7現在値 $77.880高値 $156.66

AI分析レポート

最終更新: 2025年4月30日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

ILMN: Illumina Inc. Common Stock - What's Happening and What to Watch

Stock Symbol: ILMN Generate Date: 2025-04-30 11:10:43

Alright, let's break down what's been going on with Illumina (ILMN) lately and try to figure out what it might mean. Think of this as a quick chat about the stock, cutting through the noise.

The Latest Buzz: News and Analyst Takes

Looking at the recent news, it's a bit of a mixed bag, but with a noticeable lean towards caution from the pros.

  • Several analysts have recently lowered their price targets for Illumina. Canaccord Genuity dropped theirs from $115 to $92, and Barclays went even lower, from $100 to $77. RBC Capital also trimmed their target, moving from $128 to $112, though they still keep an "Outperform" rating, which is more positive than the "Hold" or "Underweight" ratings from the others.
  • So, the general feeling from these analyst moves? They seem to think the stock isn't worth quite as much as they previously did. That's usually not a great sign for immediate price action.
  • On a more positive note, there's news about Illumina partnering with Tempus AI to work on "genomic AI innovation." This ties into a broader trend mentioned in another piece about the global AI diagnostics market growing significantly. This kind of partnership shows the company is trying to stay relevant and tap into hot areas like AI in healthcare.
  • Something important coming up is the company's First Quarter 2025 financial results, set for May 8th. Earnings reports are always a big deal and can cause the stock price to jump or drop significantly depending on the numbers and the company's outlook.

Putting the news together, you've got analysts getting a bit less optimistic on one hand, and the company pushing into exciting AI areas on the other. The upcoming earnings report is a major event that will likely shape the near future.

Checking the Price Chart: A Rocky Ride

Now, let's look at what the stock price itself has been doing. If you glance at the last few months of data, it's been a pretty tough stretch.

  • Back in late January, the stock was trading up around $130-$135. Fast forward to the end of April, and it's hovering around the mid-$70s. That's a significant drop over this period.
  • The price action hasn't been smooth sailing either. There were some sharp drops, particularly in early February and again in early March and April.
  • More recently, in April, the price seems to have found a bit of a floor, trading mostly between the low $70s and high $70s. It looks like it's been trying to stabilize after that big fall. The last recorded price on April 29th was $77.10.

What about the AI's take on the very near future? The prediction model suggests a tiny dip today (-0.08%), a small bump tomorrow (+0.13%), and then a more noticeable gain the day after (+1.71%). This hints that the AI sees some potential for a move up just beyond the immediate couple of days.

What Does This All Suggest? Outlook and Potential Moves

Based on the news, the price history, and the AI's short-term view, here's a way to think about it:

  • The Apparent Near-Term Leaning: Right now, the situation seems to lean towards a 'Hold' or 'Wait-and-See' approach, especially with the earnings report just around the corner. The analyst downgrades are a yellow flag, even if the AI partnership is a positive long-term signal. The price has stabilized recently, which is good, but it's still way down from earlier levels.
  • Why 'Hold' or 'Wait'? The market is clearly reacting to something that caused those analyst targets to drop. While the AI news is promising, it might not impact the financials immediately. The earnings report on May 8th is the next big catalyst. Waiting to see those results and the company's guidance could provide much clearer direction.
  • Potential Entry Consideration (If you're patient): If the earnings report is surprisingly positive, or if the stock holds firm around these recent levels (say, staying above the low $70s), that could be a point where some investors might consider looking closer. The AI prediction for a move up in a few days might align with a positive post-earnings reaction, but that's speculative. The recommendation data pointed to potential entry points around $76.43-$76.96, which is right where it is now, suggesting some models see this area as interesting if you believe in a bounce.
  • Potential Exit/Stop-Loss Consideration: If you currently own the stock, setting a stop-loss order below a recent low (like the $68.70 52-week low hit recently) could help protect against further significant drops, especially if the earnings report disappoints. For those looking to potentially take profits if it does bounce, the AI's potential target of $106.71 or the higher analyst targets ($92, $112) represent areas where the stock could face resistance, but these are quite a bit above the current price.

A Little More Context on Illumina

Remember, Illumina is a big player in the world of genetic and genomic analysis. They make the machines and materials used to read DNA. Their business serves research labs, hospitals, and biotech companies. The move into AI diagnostics makes sense for them, as analyzing massive amounts of genetic data is exactly where AI can help.

However, the company details also show some challenges: negative revenue growth recently, low return on equity, and relatively high debt. These fundamental points are likely part of why analysts have become more cautious, despite the potential in AI. The stock's P/E ratio around 17.4x is neutral, not screaming cheap or expensive based on current earnings.

So, it's a company with exciting technology potential but facing some current financial headwinds and analyst skepticism. The next earnings report is key.


Disclaimer: This analysis is based on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

関連ニュース

PR Newswire

Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development

Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today announced the...

もっと見る
Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
Analyst Upgrades

Canaccord Genuity Maintains Hold on Illumina, Lowers Price Target to $92

Canaccord Genuity analyst Kyle Mikson maintains Illumina with a Hold and lowers the price target from $115 to $92.

もっと見る
Canaccord Genuity Maintains Hold on Illumina, Lowers Price Target to $92
GlobeNewswire

Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations

PALM BEACH, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial intelligence (AI) is being utilized for disease detection in the global markets. In today's AI-driven world, the use of

もっと見る
Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations
PR Newswire

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and...

もっと見る
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
PR Newswire

Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025

Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8,...

もっと見る
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025
Analyst Upgrades

Barclays Maintains Underweight on Illumina, Lowers Price Target to $77

Barclays analyst Luke Sergott maintains Illumina with a Underweight and lowers the price target from $100 to $77.

AI予測Beta

AI推奨

強気

更新日時: 2025年5月3日 09:29

弱気中立強気

60.1% 信頼度

リスクと取引

リスクレベル3/5
中リスク
適しているのは
保守的
取引ガイド

エントリーポイント

$77.51

利確

$79.44

損切り

$70.09

主要因子

PDI 7.2はMDI 6.5の上にあり、ADX 8.8とともに強気トレンドを示唆しています
現在の価格はサポートレベル(77.76ドル)に非常に接近しており、強力な買い機会を示唆しています
出来高は平均(23,761)の4.3倍で、極めて強い買い圧力を示しています
MACD -0.0007はシグナルライン0.0146の下にあり、弱気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。